Australian biotechnology firm Starpharma has received Therapeutic Goods Administration approval for its anti-viral gel technology, which will likely be sold in Australia in Ansell condoms within months.
Starpharma’s VivaGel is an anti-viral gel providing protection against HIV, human papilloma virus and herpes. It will be launched in Australia under Ansell’s LifeStyle Dual Protect line.
Yesterday it was announced that the innovation had received Conformity Assessment certification from the TGA, described as similar to European CE certification.
"There is a final step, which is a relatively rapid step which is likely to be a matter of a few weeks for listing on the ARTG," said Starpharma’s chief executive Dr Jackie Fairley, according to the ABC.
"The product will be, therefore, expected to be launched quite soon, so probably within the next few months."
According to a joint statement from the two companies, tests have shown that 99.9 per cent of HIV, herpes and other sexually transmitted disease viruses can be rendered inactive.
Starpharma would receive royalties from sales of Ansell condoms using the product.
“Our partnership with Starpharma is a great example of two highly innovative Australian businesses working together to bring to market a ground-breaking new sexual health product,” said Peter Carroll, the leader of Ansell’s Sexual Wellness Global Business Unit.
“New product development is central to Ansell’s business strategy and this highly innovative product is exciting for both companies.”
VivaGel last week gained approval from the US Food and Drug Administration for clinical trials for bacterial vaginosis.
AAP reports that the compound has approval to be sold in Japan under licence through Okamoto Industries, the country’s biggest condom manufacturer.